Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 426115 plus metformin versus placebo plus metformin in type 2 diabetes mellitus
2013-002172-40Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2019
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing ISIS 426115 + metformin with Placebo + metformin (2 arms). Primary endpoint: Change from baseline to Week 7 in serum fructosamine concentration. Started Jul 2019; status: completed.
02
Drugs
GCCR ASO
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-002172-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002172-40.